Literature DB >> 12780717

Nitric oxide and cellular immunity in experimental cutaneous leishmaniasis.

N L Díaz1, M Fernández, E Figueira, R Ramírez, I B Monsalve, F J Tapia.   

Abstract

We examined the local and systemic production of nitric oxide (NO) and the pattern of cytokine during the course of Leishmania mexicana infection in susceptible BALB/c and resistant C57BL/6 mice. NO derivatives were measured in serum, and the expression of inducible nitric oxide synthase (iNOS), interferon (IFN-gamma), interleukin (IL-4) and epidermal Langerhans cells (LC) was measured in the lesions by immunohistology. Circulating NO concentrations, iNOS+ cell density, IFN-gamma+ Th1 cells and CD205+ Langerhans cells were higher in early lesions of resistant C57BL/6 mice. In contrast, susceptible BALB/c mice developed chronic and progressive lesions with a predominance of IL-4+ Th2 cells. In both susceptible and resistant mice, lesion size and lymph node volume followed a similar course. The early local and systemic production of NO in resistant mice may be related with the premature production of IFN-gamma observed, contributing to the resolution of the lesion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780717     DOI: 10.1046/j.1365-2230.2003.01206.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  6 in total

1.  A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis.

Authors:  Patricio López-Jaramillo; Melvin Y Rincón; Ronald G García; Sandra Y Silva; Erin Smith; Piyaporn Kampeerapappun; Carlos García; Daniel J Smith; Marcos López; Iván D Vélez
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

2.  Expression of inducible nitric oxide synthase in human cutaneous leishmaniasis.

Authors:  Gamze Serarslan; Esin Atik
Journal:  Mol Cell Biochem       Date:  2005-12       Impact factor: 3.396

3.  LXR deficiency confers increased protection against visceral Leishmania infection in mice.

Authors:  Kevin W Bruhn; Chaitra Marathe; Ana Cláudia Maretti-Mira; Hong Nguyen; Jacquelyn Haskell; Thu Anh Tran; Veena Vanchinathan; Upasna Gaur; Mary E Wilson; Peter Tontonoz; Noah Craft
Journal:  PLoS Negl Trop Dis       Date:  2010-11-16

4.  Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629].

Authors:  Sandra Y Silva; Ligia C Rueda; Marcos López; Iván D Vélez; Christian F Rueda-Clausen; Daniel J Smith; Gerardo Muñoz; Hernando Mosquera; Federico A Silva; Adriana Buitrago; Holger Díaz; Patricio López-Jaramillo
Journal:  Trials       Date:  2006-05-15       Impact factor: 2.279

5.  Adoptive transfer of dendritic cells modulates immunogenesis and tolerogenesis in a neonatal model of murine cutaneous leishmaniasis.

Authors:  Loida V Ponce; José Corado; Nilka L Díaz; Felix J Tapia
Journal:  Kinetoplastid Biol Dis       Date:  2005-01-25

6.  The Influence of Infection by Different Leishmania (Viannia) braziliensis Isolates on the Pathogenesis of Disseminated Leishmaniasis.

Authors:  Walker N Oliveira; Andreza S Dórea; Pedro P Carneiro; Maurício T Nascimento; Lucas P Carvalho; Paulo R L Machado; Albert Schriefer; Olívia Bacellar; Edgar M Carvalho
Journal:  Front Cell Infect Microbiol       Date:  2021-09-10       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.